Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Purchases of marketable securities | (120,605) | (242,399) |
| Proceeds from sales and maturities of marketable securities | 62,269 | 239,278 |
| Proceeds from working capital adjustments on acquisition | 710 | — |
| Purchases of property and equipment | (7,914) | (2,513) |
| Net cash used in investing activities | (65,540) | (5,634) |
| Financing activities | ||
| Repurchase of common stock | (332,729) | (303,489) |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 4,865 | 1,202 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's capex?
- Halozyme Therapeutics (HALO) reported capex of $4.17M in Q2 2026.
- How has Halozyme Therapeutics's capex changed year-over-year?
- Halozyme Therapeutics's capex increased by 167.0% year-over-year, from $1.56M to $4.17M.
- What is the long-term trend for Halozyme Therapeutics's capex?
- Over 3 years (2021 to 2025), Halozyme Therapeutics's capex has grown at a 68.5% compound annual growth rate (CAGR), from $1.46M to $6.97M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Halozyme Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude